Spain Fragile-X Syndrome Therapeutics Market Analysis

Spain Fragile-X Syndrome Therapeutics Market Analysis


$ 3999

Spain Fragile-X Syndrome Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The most typical cause of inherited learning disabilities is fragile X syndrome (FXS), an X-linked genetic disorder. The global market is driven by the higher prevalence of males than females, the transmission of the disease from one generation to the next, and the rise in patients suffering from this and other genetic disorders. Aelis Farma Sas, Alcobra Ltd, Amo Pharma Limited, Confluence Pharmaceuticals Llc, F. Hoffmann-la Roche Ltd., Marinus Pharmaceuticals, Mi.to. Technology S.r.l., Neuren Pharmaceuticals Limited, Ovid Therapeutics Inc., Sage Therapeutics, Acadia Pharmaceuticals, Advanz Pharma Corp, Boehringer Ingelheim, GlaxoSmithKline, H. Lundbeck, Janssen, Novartis, Ots.

ID: IN10ESRD025 CATEGORY: Rare Diseases GEOGRAPHY: Spain AUTHOR: Sakshi Mantri

Buy Now

Spain Fragile-X Syndrome Therapeutics Market Analysis Summary

Spain Fragile-X Syndrome Therapeutics Market is valued at around $0.49 Mn in 2022 and is projected to reach $0.77 Mn by 2030, exhibiting a CAGR of 6% during the forecast period 2023-2030.

The most typical cause of inherited learning disabilities is fragile X syndrome (FXS), an X-linked genetic disorder. The fragile X mental retardation 1 (FMR1) gene's 5' untranslated region has expanded CGG trinucleotide repeats, which are the root cause of FXS. The FMR1 gene is transcriptionally silenced as a result of this enlargement, which also causes the fragile X mental retardation protein (FMRP) to express less or not at all. FMRP has a key role in mediating synaptic plasticity and dendritic development.

A spectrum of behavioural and developmental problems, including poor eye contact, ADHD, anxiety, and other psychiatric and neurologic symptoms, are all part of the lifelong illness known as FXS (seizures and movement disorders). Other prevalent characteristics of the syndrome include physical characteristics including long faces, flat feet, and huge, prominent ears, as well as hearing brought on by the high recurrence of ear infections. The global market is driven by the higher prevalence of males than females, the transmission of the disease from one generation to the next, and the rise in patients suffering from this and other genetic disorders.

Aelis Farma Sas, Alcobra Ltd, Amo Pharma Limited, Confluence Pharmaceuticals Llc, F. Hoffmann-la Roche Ltd., Marinus Pharmaceuticals, Mi.to. Technology S.r.l., Neuren Pharmaceuticals Limited, Ovid Therapeutics Inc., Sage Therapeutics, Acadia Pharmaceuticals, Advanz Pharma Corp, Boehringer Ingelheim, GlaxoSmithKline, H. Lundbeck, Janssen, Novartis, Ots

Market Dynamics

Market Drivers

The global market is driven by the higher occurrences of males compared to females and the transmission of the disease from one generation to the next, which increases the number of patients with this and many other genetic disorders. The market is growing as a result of rising demand for specialised drugs to treat the problems caused by genetic abnormalities as well as increased financial assistance for researchers developing novel therapies. Increased research and development projects, mergers, and manufacturer cooperation to treat disease all have an effect on the market. Additionally, medical spending has increased, technology has advanced, and the prevalence of genetic illnesses has increased.

Market Development

The global market for this and many other genetic illnesses is driven by the higher occurrences of males relative to females and the transmission of the disease from one generation to the next. The market is growing due to rising demand for specialised pharmaceuticals to treat the problems caused by genetic abnormalities as well as increased financial assistance for researchers developing novel therapies. The rise in R&D projects, mergers, and manufacturer alliances to treat diseases all have an impact on the market. Additionally, medical spending has increased, technology has advanced, and genetic problems are becoming more common.

Key players

Vertex Pharmaceuticals Sarepta Therapeutics Spark Therapeutics Pfizer Alnylam Pharmaceuticals Protalix BioTherapeutics BioMarin Pharmaceutical Orchard Therapeutics uniQure CRISPR Therapeutics

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For Spain Fragile-X Syndrome Therapeutics Market

By Drug

  • SSRIs (Fluoxetine, Sertraline, Citalopram, Escitalopram)
  • Other Antidepressants (Venlafaxine, Bupropion, Trazadone)
  • Psychostimulants (Methylphenidate Hydrochloride)
  • Atypical Antipsychotics (Aripiprazole, Risperidone)
  • Anticonvulsants (Lamotrigine, Carbamazepine, Sodium Valproate)
  • Antihypertensive Anxiolytics (Clonidine, Guanfacine)
  • Benzodiazepines (Clonazepam, Diazepam)
  • Lithium (Lithium Carbonate)

By End User

  • Clinic
  • Hospital
  • Research Center

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 04 July 2023
Updated by: Shivam Zalke

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up